一分钟看懂
这是一项关于食管鳞状细胞癌的II 期研究，登记的药物或干预包括Adebrelimab: 1200 mg day1, Q3W, 3 times，当前状态为研究进行中，已停止招募。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Adebrelimab: 1200 mg day1, Q3W, 3 times · II 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为不限性别，年龄18岁至75岁；以下仅摘录6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Nanfang Hospital, Southern Medical University · 广州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Age 18-75 years old, gender unlimited
- 2. Esophageal squamous cell carcinoma confirmed by histology and unresectable locally advanced or postoperative recurrence
- 3. According to the solid tumor efficacy evaluation criteria (RECIST1.1), there is at least one measurable lesion; And the lesion had not received prior radiotherapy
- 4. ECOG: 0\~1
- 5. Expected survival ≥12 weeks 6. Laboratory examination: neutrophils ≥1.5 x 109/L, platelets ≥100 x 109/L; Hemoglobin ≥ 9g/L; Albumin ≥ 2.8g/dL; Bilirubin ≤1.5 times ULN, ALT and AST≤2.5 times ULN
- 7: Subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up 8: Tissue samples should be provided for biomarker analysis such as (PD-L1). Newly acquired tissues are preferred, and 15 5-6um thick paraffin sections can not be provided for archiving by the recent organizer
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06885814；登记信息更新于 2026-10-02；本站同步于 2026-10-08，中国中心当前名额未经人工确认。